cemiplimab

02/01/2021 - "Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report."
01/01/2022 - "Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma."
02/01/2021 - "Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma."
11/01/2023 - "This single-arm, multicentre, phase 2 study included patients aged 18 years or older with resectable stage II-IV (M0) cutaneous squamous cell carcinoma and Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received up to four planned doses of neoadjuvant cemiplimab 350 mg intravenously every 3 weeks followed by curative-intent surgery. "
11/01/2023 - "Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study."

01/01/2021 - "Cemiplimab may significantly increase overall survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 level of at least 50%. "
01/01/2021 - "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial."
01/01/2023 - "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study."
01/01/2022 - "Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer."
01/01/2022 - "The EMPOWER-Lung 1 trial showed that cemiplimab significantly prolongs the duration of progression-free survival and overall survival in advanced non-small cell lung cancer (NSCLC) patients with at least 50% programmed cell death receptor ligand-1 (PD-L1) positivity, yet the financial burden may limit its use. "

01/01/2021 - "Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years."
02/01/2020 - "cemiplimab) are also effective in the treatment of basal cell carcinomas. "
01/01/2023 - "Cemiplimab is approved for the treatment of locally advanced basal cell carcinomas (BCC), although with mitigated results. "
03/01/2022 - "Cemiplimab for locally advanced and metastatic basal cell carcinoma."
01/01/2022 - "Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again."

01/01/2023 - "Real-world studies demonstrated cemiplimab efficacy in periorbital tumors, tumors with large caliber perineural invasion, and tumors in solid organ transplant recipients. "
01/01/2021 - "Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. "
01/01/2021 - "Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies."
10/26/2023 - "Conclusions: Baseline tumor load (i.e., MTV and TLG) and metabolic response at 12 weeks may have a prognostic impact in cSCC patients treated with cemiplimab."
09/01/2023 - "Across tumor types, the immunogenicity of cemiplimab was low, with an overall treatment-emergent ADA incidence rate of 1.9% and 2.5% at intravenous dose regimens of 3 mg/kg every 2 weeks and 350 mg every 3 weeks, respectively. "

01/01/2023 - "The efficacy of cemiplimab in recurrent cervical cancer has been demonstrated in the clinical trial EMPOWER-Cervical 1. However, its high price makes patients and clinicians hesitate to use it. "
01/01/2023 - "From the American public payers' perspective, cemiplimab is a cost-effective treatment option for second-line treatment of recurrent cervical cancer. "
01/01/2022 - "Recently, the phase 3 trial EMPOWER-Cervical 1 has investigated cemiplimab in patients with recurrent/metastatic cervical cancer. "
11/01/2022 - "Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer."
10/01/2022 - "Survival with Cemiplimab in Recurrent Cervical Cancer."